Realta Life Sciences secured an additional $40 million in the final tranche of its Series A, bringing total raised to more than $150 million for its hypoxic ischemic encephalopathy (HIE) treatment. The company’s fundraising underscores investor appetite for neurocritical-care interventions aimed at mitigating injury after birth complications. HIE remains a leading cause of neonatal morbidity, and late-stage execution depends on translating preclinical and early clinical signals into measurable outcomes and scalable study designs. The round supports Realta’s runway as it advances toward key development milestones, with capital targeted at building clinical momentum in an area where time-to-intervention and endpoint performance are tightly scrutinized.